- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00335114
Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers
May 5, 2023 updated by: Carol E. Rosenstiel, University of Alabama at Birmingham
Cyclosporine Ophthalmic Emulsion is currently used in the treatment of dry eye syndrome.
Contact lens wearers frequently suffer from dry eye syndrome.
The purpose of this study is to evaluate cyclosporine ophthalmic emulsion verses re-wetting drops in the relief of dry eye symptoms in contact lens wearers
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- UAB Ophthalmology Services Foundation
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- contact lens wearer
- clinical diagnosis of dry eye syndrome
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Ocular exams and questionnaires at baseline and at 3 months will determine
|
the effect of cyclosporine on dry eye syndrome.
|
Secondary Outcome Measures
Outcome Measure |
---|
Increased contact lens wearing time due to a decrease in severity
|
of dry eye symptoms
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Carol E Rosenstiel, OD, University of Alabama at Birmingham
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2005
Study Completion
April 1, 2006
Study Registration Dates
First Submitted
June 7, 2006
First Submitted That Met QC Criteria
June 7, 2006
First Posted (Estimate)
June 8, 2006
Study Record Updates
Last Update Posted (Actual)
May 9, 2023
Last Update Submitted That Met QC Criteria
May 5, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Eye Diseases
- Disease
- Lacrimal Apparatus Diseases
- Keratoconjunctivitis
- Conjunctivitis
- Conjunctival Diseases
- Keratitis
- Corneal Diseases
- Syndrome
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Antifungal Agents
- Calcineurin Inhibitors
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- F051025017
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contact Lens Wearers With Dry Eye Syndrome
-
Abbott Medical OpticsCompletedNormal Contact Lens WearersCanada
-
Alcon ResearchCompletedSymptomatic Contact Lens WearersUnited States
-
Alcon ResearchCompletedHealthy Contact Lens WearersUnited States
-
Abbott Medical OpticsCompletedStudy Focus is Healthy Contact Lens WearersUnited States
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityCompletedContact Lens Discomfort | Questionnaire | Contact LensChina
-
Centre for Contact Lens ResearchCoopervision, Inc.CompletedContact Lens Related Dry EyeCanada
-
OptovueCompleted
-
Optometric Technology Group LtdAllerganCompletedContact Lens Related Dry Eye SyndromeUnited Kingdom
-
Jennifer FogtCompleted
-
University of Alabama at BirminghamAlcon ResearchCompleted
Clinical Trials on cyclosporine ophthalmic emulsion
-
AllerganCompletedDry Eye SyndromesUnited States
-
AllerganCompletedArthritis, Rheumatoid | Lupus Erythematosus, Systemic | Scleroderma, Systemic | Keratoconjunctivitis Sicca | Sjogren's SyndromeUnited States
-
Skye Bioscience, Inc.CompletedPrimary Open Angle Glaucoma | Ocular HypertensionUnited States
-
Taejoon Pharmaceutical Co., Ltd.CompletedDry Eye | Dry Eye SyndromesKorea, Republic of
-
Campus Bio-Medico UniversityCompletedOcular Inflammation | Ocular Surface DiseaseItaly
-
Aurinia Pharmaceuticals Inc.Completed
-
Boehringer IngelheimCompletedLymphoma, Large B-Cell, DiffuseSpain, Italy, Belgium
-
AllerganCompleted
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Myelodysplastic/Myeloproliferative NeoplasmsUnited States